Clients

Acumen Detection worked with researchers at Cornell University to develop innovative assays and incorporate Real-Time PCR for detection that is specific, sensitive and rapid. We also introduced the Acu-POLARIS (Portable Onsite Laboratory And Rapid Identification System), empowering producers to make faster, more informed management decisions.
Contact: sales@acumendetection.com

ANDRO is a small, for-profit research and development company.  The company is headquartered in Rome, NY with offices in Dayton, OH, and now at the CNY Biotech Accelerator in Syracuse, NY, with a soon to be established office in the Washington, DC area.  The company focuses on defense-related technologies in the areas of:

• Radio Frequency (RF) Spectrum Management
• Electromagnetic Environmental Effects (E3) computer modeling, simulation and analysis
• Computational Electromagnetics (CEM) tool development
• Cognitive Software Defined Radio (SDR) technologies
• Secure RF Wireless Communications
• Cyber-domain Spectrum Exploitation
• Cyber Electromagnetic Activities (CEMA)
• Sensor Resource Management (SRM)
• Multisensor Data Fusion

Our commercial subsidiary, Spectrum Fusion, Inc. is an ANDRO company that focuses on Autonomous Systems technologies and applications for the Internet of Things marketplace with special emphasis on UAS/V Command and Control (C2) technologies, medical sensing devices and emerging technologies for “big data” management.  Spectrum Fusion provides Spectrum Management as a Service (SMaaS) functions to industry focusing on independent RF spectrum analysis and testing pre-certification services including performance of spectrum site surveys

ANDRO is a recognized leader and member of the National Spectrum Consortium (NSC). The company was awarded the coveted Tibbetts Award from the Small Business Administration (SBA) for Excellence in the Federal Small Business Innovation Research (SBIR) Program and was presented the award at the White House in 2015.  ANDRO is also the catalyst for its non-profit activity called The Project FibonacciÒ Foundation, Inc., which provides youth-centered alternative learning and cross-education programs in STEAM (Science, Technology, Engineering, Arts & Math) disciplines.

2018 MDIC Graduate

AptaMatrix Inc. is a biotechnology firm leveraging next-gen sequencing technology to accelerate aptamer discovery. Aptamers are non-coding nucleic acid molecules that have the ability to bind to protein targets will high affinity and specificity. Aptamers are the nucleic acid equivalent of a monoclonal antibody, and viable as therapeutic agents and for detection/diagnostic applications. Using AptaMatirx's proprietary workflow, aptamer discovery can be reduced to 2 weeks with an anticipated reduction to 3 days. AptaMatrix specializes in screening modified nucleic acid libraries that are difficult to screen using traditional SELEX aptamer discovery methods.
NIH Small Business Innovation Research Phase II Awardee, 2020 - $2M
Contact:  http://www.aptamatrix.com/contact.html 

Aurie is developing a safely reusable intermittent urinary catheter system in order to raise the standard of care for people with neurogenic bladder while reducing overall healthcare costs.  Started after the founder's close family member sustained a spinal cord injury and became reliant on urinary catheters, Aurie is committed to developing a user-centered urinary catheterization system that is sustainable, affordable, and above all, healthy. The system consists of a reusable, customizable, no-touch intermittent catheter and a portable catheter carrying case that cleans, disinfects, and lubricates catheters on-the-go with pre-packaged cleaning supplies. 
Selected as a 2019 FuzeHub Commercialization Competition finalist.
2020 MDIC Graduate
Connect:  https://livewithaurie.com/contact-hyde 

CMTx Biotech is a drug development company working to commercialize a pipeline of proprietary, non-antibiotic, chemically-modified tetracycline (CMT) compositions and formulations for the treatment of diseases with high unmet need, including those with no FDA approved products, rare and pediatric conditions, and indications of critical importance to national defense and homeland security

Our mission is to equip mainly Life Science but also Engineering firms with products & services allowing them to take advantage of modeling and simulations to timely develop processes and devices. Our software can streamline complex manipulations, reduce time on task, and increase the quality of end products. We are also prepared to prototype complex electronic and more specifically Medical devices. With us design starts with a good understanding of the underlying processes which we usually model. Simulations enable to draw more precise specifications. This way we conceive effective prototypes in just a few iterations. 

Cormac Life Sciences is a Veterans Affairs and New York State certified Service Disabled Veteran-Owned Small Business (SDVOSB) delivering life sciences research and support services.  

We provide expertise across a range of biopreparedness disciplines to include biosurveillance, basic and translational sciences, clinical research, and essential support services such as quality assurance, field site development and regulatory affairs services.

We are led by physician-scientists, technology executives, and health care business development experts with established connections across government, industry and academia.

Our mission is to support global health security and biopreparedness objectives. We are committed to providing innovative, agile and client-centered solutions with a focus on New York State and U.S. Government clients

Dancing Eyes is a biotech start-up committed to helping healthcare providers overcome the complexity and entanglement of diagnosing eye movement disorders via a virtual-reality system. Diagnosing the reason behind vertigo, double vision or, misaligned eyes can be a daunting task for the non-specialized physician. Whether the cause is benign such as an inner ear infection, or life-threatening such as a stroke, our technology can capture their signature mark on eye movements via a quick, automated, virtual reality-based examination, and help healthcare providers in confidently making the correct diagnosis.

EndoGlow produces fluorescent medical devices to enhance visualization during minimally invasive surgeries. 

​The need for more visual information to improve real time decision making inspired the creation of EndoGlow’s fluorescence based Tissue Reveal Technology™.  Designed to work in conjunction with camera systems that image NIR, EndoGlow’s  cutting-edge technology embeds fluorescence into surgical tools, eliminating the need to inject ICG or other dyes.

​By embedding fluorescence,  EndoGlow’s products trans-illuminate tissues in order to visualize subsurface pathology, surgical planes and relative tissue depth.

Named "Top 10 Minimially Invasive Device Solution Providers of 2020" by MedTech Outlook
2017 MDIC Graduate

Expressive Neuroscience is developing an industry-leading assay platform to evaluate CNS gene therapy vectors. This platform will combine cutting edge informatics, tissue handling, DNA sequencing and imaging technologies. The precision, power, and scale of the Expressive platform will provide the clear metrics required to move the most promising candidate vectors toward the clinic. The Expressive Neuroscience team has the deep expertise in neuroscience, informatics and assay development.

Contact:  info@expressiveneuro.com 

JelikaLite is developing CognilumTM, an innovative solution to reduce a child's autism symptoms, enabling better integration into society and improving family's quality of life. It is an intelligent wearable medical device, combining therapeutic non-invasive brain stimulation with near infrared light, EEG sensors and a personalization platform. Based on the results of its Phase I placebo-controlled, double-blind clinical trial, the FDA granted JelikaLite a Breakthrough Device Designation, for the reduction of symptoms of autism in pediatric patients aged 2 to 6.    Our goal is to demystify autism - by collecting data about the brain's electrophysiological activity and corresponding behavioral symptoms, Cognilum will “open a window” into the child's brain, monitor the child's symptoms and ultimately predict each child’s developmental trajectory. It will empower both parents and doctors to precisely deliver the needed personalized treatments.

Developing solutions for important global health issues

Syracuse Biolabs, Inc. (SBL) is a Syracuse, NY based biotech firm which “accelerates bioinnovation through collaboration.” Syracuse Biolabs is a for-profit S corporation focused on meeting its corporate mission by partnering with academic and start-up laboratories and leveraging federal funding mechanisms to drive novel biotechnologies from early stage funding through commercialization. Syracuse Biolabs founder, Dr. Mark McPike, has 15+ years preparing SBIR-STTR applications and leading funded Phase I and II SBIR-STTR projects as Principal Investigator (PI) and Co-PI. Dr. McPike has led projects from NIH, AFRL, HSARPA, and DOD.  

http://www.syrbiolabs.com

Therapha™ is a conversational chatbot that uses patient-reported symptoms and history to provide comprehensive musculoskeletal triaging, decision support, and document automation at the point of care. Our approach combines evidence-based research, expert knowledge, and advanced technology to augment clinicians in making informed decisions at the point of care. Therapha is a patient-facing Clinical Decision Support solution (CDSS) that automates over 80% of administrative work for the clinician while providing cognitive aid. Our synthetic human interacts with patients before their in-person or telehealth visit, thereby integrating seamlessly into the clinical workflow. Therapha is designed for all stakeholders and aims to bridge the gap between research and practice. We have secured a blocking US patent and patent pending in EU and Australia.

Connect with us: contact@therapha.com

Triton Bio is developing a new diagnostic test to rapidly determine the antibiotic resistance of bacteria and fungi causing life-threatening infections. Current laboratory tests take 2-5 days to provide results, and these delays jeopardize patient safety and significantly increase the cost of treatment. Triton Bio will enable lab personnel to automatically capture and analyze pathogenic microbes directly from biological fluids and swabs without the need to first grow microbes in culture. This technology will yield results in less than 90 minutes, thereby empowering doctors to choose the right antibiotics at the right time and improve clinical outcomes for patients. The company’s core technology was developed with support from DARPA between 2016-2017. Since then the founders have conducted over 350 interviews with key stakeholders with support from the National Science Foundation Innovation Corps. In July 2019 the company was awarded a SBIR Phase I grant from the National Science Foundation.

ZephyRx creates video games for respiratory therapy. Our games coupled with a custom, breath­activated game controller have shown to increase patient compliance as much as 20X.  In our $1.8M NIH­sponsored clinical trial we apply video games to well­known respiratory therapy exercises to address pneumonia, asthma, COPD and cystic fibrosis. We started our business in 2007 and design, produce and sell worldwide breath­powered musical instruments and breath­powered video game controllers for the disabled. 

Zetagen Therapeutics (formerly Fusologics), is a pre-clinical orthopedics company developing products that activate a novel and proprietary molecular pathway for growing bone.  Discovered by accident, Fusologics' first product, Nalfuse, addresses a large unmet need for the $4b orthobiologics market and several high volume medical applications for which bone growth leads to optimal outcomes. Based on published pre-clinical data, Nalfuse activates this molecular pathway with a combination of a collagen carrier and an FDA-approved small molecule with over 40 years of high dosage, systemic clinical use for a different indication. As opposed to other products on the market that contain biologic growth factors, such as Medtronic's Infuse (BMP2), which at its peak accounted for ~$900m revenue per year but has since seen a precipitous decline in use due to high cancer risk and significant side effects, Nalfuse has shown the potential to be safer, significantly less costly to manufacture and grow bone just as effectively, if not better.